Anisomycin #2222
Western blot analysis of extracts from 293T cells, treated with Anisomycin (25 μg/ml) for the indicated times, with or without pretreatment with JNK inhibitor SP600125 (50 μM, 40 min; +), using Phospho-JunB (Thr102/Thr104) (D3C6) Rabbit mAb #8053 (upper) or JunB (C37F9) Rabbit mAb #3753 (lower).
- Related Products
Product Information
Product Usage Information
Anisomycin is supplied as a lyophilized powder. For a 25 mg/ml stock, reconstitute the 10 mg in 400 µl DMSO. Working concentrations and length of treatments vary depending on the desired effect, but it is typically used at 5-50 µg/ml for 5-60 minutes. Soluble in DMSO or MeOH.
Storage
Store lyophilized at -20C. Protect from light. In lyophilized form, the chemical is stable for 24 months. Once in solution, use within 1 month and store at -20C. Aliquot to avoid multiple freeze/thaw cycles.
Product Description
| Molecular Weight | 265.3 g/mol |
| Purity | >98% |
| Molecular Formula | C14H19NO4 |
| CAS | 22862-76-6 |
| Solubility | Soluble in DMSO at 100mg/ml and MeOH at 50mg/ml. |
Background
Anisomycin, an antibiotic produced by Streptomyces griseolus and S. roseochromogenes, was originally described to inhibit protein-protein synthesis at the translational level (1). More recently, it is has been well characterized to strongly activate the stress kinases SAPK/JNK and p38 MAPK, as well as p70/85 S6 kinase in mammalian cells, which results in the rapid induction of immediate-early (IE) genes, such as c-fos, fosB, c-jun, JunB, and JunD (1). Investigators have demonstrated that anisomycin acts as a potent signaling agonist, synergizing with growth factors and phorbol esters to superinduce these IE genes (1,2). Research studies have demonstrated that anisomycin induces apoptosis in many cancer cell lines (3-5).
- Hazzalin, C.A. et al. (1998) Mol Cell Biol 18, 1844-54.
- Kardalinou, E. et al. (1994) Mol Cell Biol 14, 1066-74.
- Kochi, S.K. and Collier, R.J. (1993) Exp Cell Res 208, 296-302.
- Törocsik, B. and Szeberényi, J. (2000) Biochem Biophys Res Commun 278, 550-6.
- Curtin, J.F. and Cotter, T.G. (2002) Br J Cancer 87, 1188-94.
限制使用
除非 CST 的合法授书代表以书面形式书行明确同意，否书以下条款适用于 CST、其关书方或分书商提供的书品。 任何书充本条款或与本条款不同的客书条款和条件，除非书 CST 的合法授书代表以书面形式书独接受， 否书均被拒书，并且无效。
专品专有“专供研究使用”的专专或专似的专专声明， 且未专得美国食品和专品管理局或其他外国或国内专管机专专专任何用途的批准、准专或专可。客专不得将任何专品用于任何专断或治专目的， 或以任何不符合专专声明的方式使用专品。CST 专售或专可的专品提供专作专最专用专的客专，且专用于研专用途。将专品用于专断、专防或治专目的， 或专专售（专独或作专专成）或其他商专目的而专专专品，均需要 CST 的专独专可。客专：(a) 不得专独或与其他材料专合向任何第三方出售、专可、 出借、捐专或以其他方式专专或提供任何专品，或使用专品制造任何商专专品，(b) 不得复制、修改、逆向工程、反专专、 反专专专品或以其他方式专专专专专品的基专专专或技专，或使用专品开专任何与 CST 的专品或服专专争的专品或服专， (c) 不得更改或专除专品上的任何商专、商品名称、徽专、专利或版专声明或专专，(d) 只能根据 CST 的专品专售条款和任何适用文档使用专品， (e) 专遵守客专与专品一起使用的任何第三方专品或服专的任何专可、服专条款或专似专专
For Research Use Only. Not For Use In Diagnostic Procedures.
Cell Signaling Technology is a trademark of Cell Signaling Technology, Inc.
All other trademarks are the property of their respective owners. Visit our
Trademark Information page.